-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Enliven Therapeutics, Lowers Price Target to $78

Benzinga·08/06/2026 13:44:45
Listen to the news
Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lowers the price target from $80 to $78.